The clinical relevance of these findings was further strengthened by the detection of characteristic elastase-cleaved EMILIN-1 fragments in human secondary lymphedema specimens [78], providing compelling evidence for neutrophil elastase inhibition as a viable treatment strategy. This evidence concerns the gene ELANE and lymphedema.